Cenderitide-Eluting Film for Potential Cardiac Patch Applications

Xu Wen Ng, Yingying Huang, Horng Haur Chen, John C Jr. Burnett, Freddy Y C Boey, Subbu S. Venkatraman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cenderitide, also known as CD-NP, is a designer peptide developed by combining native mammalian c-type natriuretic peptide (CNP) and the C-terminus isolated from the dendroapis natriuretic peptide (DNP) of the venom from the green mamba. In early studies, intravenous and subcutaneous infusion of cenderitide was reported to reduce left ventricular (LV) mass and ameliorate cardiac remodelling. In this work, biodegradable polymeric films encapsulating CD-NP were developed and were investigated for their in vitro release and degradation characteristics. Subsequently, the bioactivity of released peptide and its effects on human cardiac fibroblast (HCF) were explored. We achieved sustained release from three films with low, intermediate and high release profiles for 30 days. Moreover, the bioactivity of released peptide was verified from the elevated production of cyclic guanosine monophospate (cGMP). The CD-NP released from films was able to inhibit the proliferation of hypertrophic HCF as well as suppress DNA synthesis in HCF. Furthermore, the sustained delivery from films showed comparable or superior suppressive actions on hypertrophic HCF compared to daily infusion of CD-NP. The results suggest that these films could be used to inhibit fibrosis and reduce cardiac remodelling via local delivery as cardiac patches.

Original languageEnglish (US)
Article numbere68346
JournalPLoS One
Volume8
Issue number7
DOIs
StatePublished - Jul 4 2013

Fingerprint

Fibroblasts
fibroblasts
natriuretic peptides
peptides
Bioactivity
Peptides
C-Type Natriuretic Peptide
Elapidae
Subcutaneous Infusions
guanosine
Natriuretic Peptides
biodegradability
Guanosine
Venoms
venoms
fibrosis
Polymer films
Intravenous Infusions
Fibrosis
Degradation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cenderitide-Eluting Film for Potential Cardiac Patch Applications. / Ng, Xu Wen; Huang, Yingying; Chen, Horng Haur; Burnett, John C Jr.; Boey, Freddy Y C; Venkatraman, Subbu S.

In: PLoS One, Vol. 8, No. 7, e68346, 04.07.2013.

Research output: Contribution to journalArticle

Ng, Xu Wen ; Huang, Yingying ; Chen, Horng Haur ; Burnett, John C Jr. ; Boey, Freddy Y C ; Venkatraman, Subbu S. / Cenderitide-Eluting Film for Potential Cardiac Patch Applications. In: PLoS One. 2013 ; Vol. 8, No. 7.
@article{999845906da24d608a734dab5335c573,
title = "Cenderitide-Eluting Film for Potential Cardiac Patch Applications",
abstract = "Cenderitide, also known as CD-NP, is a designer peptide developed by combining native mammalian c-type natriuretic peptide (CNP) and the C-terminus isolated from the dendroapis natriuretic peptide (DNP) of the venom from the green mamba. In early studies, intravenous and subcutaneous infusion of cenderitide was reported to reduce left ventricular (LV) mass and ameliorate cardiac remodelling. In this work, biodegradable polymeric films encapsulating CD-NP were developed and were investigated for their in vitro release and degradation characteristics. Subsequently, the bioactivity of released peptide and its effects on human cardiac fibroblast (HCF) were explored. We achieved sustained release from three films with low, intermediate and high release profiles for 30 days. Moreover, the bioactivity of released peptide was verified from the elevated production of cyclic guanosine monophospate (cGMP). The CD-NP released from films was able to inhibit the proliferation of hypertrophic HCF as well as suppress DNA synthesis in HCF. Furthermore, the sustained delivery from films showed comparable or superior suppressive actions on hypertrophic HCF compared to daily infusion of CD-NP. The results suggest that these films could be used to inhibit fibrosis and reduce cardiac remodelling via local delivery as cardiac patches.",
author = "Ng, {Xu Wen} and Yingying Huang and Chen, {Horng Haur} and Burnett, {John C Jr.} and Boey, {Freddy Y C} and Venkatraman, {Subbu S.}",
year = "2013",
month = "7",
day = "4",
doi = "10.1371/journal.pone.0068346",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Cenderitide-Eluting Film for Potential Cardiac Patch Applications

AU - Ng, Xu Wen

AU - Huang, Yingying

AU - Chen, Horng Haur

AU - Burnett, John C Jr.

AU - Boey, Freddy Y C

AU - Venkatraman, Subbu S.

PY - 2013/7/4

Y1 - 2013/7/4

N2 - Cenderitide, also known as CD-NP, is a designer peptide developed by combining native mammalian c-type natriuretic peptide (CNP) and the C-terminus isolated from the dendroapis natriuretic peptide (DNP) of the venom from the green mamba. In early studies, intravenous and subcutaneous infusion of cenderitide was reported to reduce left ventricular (LV) mass and ameliorate cardiac remodelling. In this work, biodegradable polymeric films encapsulating CD-NP were developed and were investigated for their in vitro release and degradation characteristics. Subsequently, the bioactivity of released peptide and its effects on human cardiac fibroblast (HCF) were explored. We achieved sustained release from three films with low, intermediate and high release profiles for 30 days. Moreover, the bioactivity of released peptide was verified from the elevated production of cyclic guanosine monophospate (cGMP). The CD-NP released from films was able to inhibit the proliferation of hypertrophic HCF as well as suppress DNA synthesis in HCF. Furthermore, the sustained delivery from films showed comparable or superior suppressive actions on hypertrophic HCF compared to daily infusion of CD-NP. The results suggest that these films could be used to inhibit fibrosis and reduce cardiac remodelling via local delivery as cardiac patches.

AB - Cenderitide, also known as CD-NP, is a designer peptide developed by combining native mammalian c-type natriuretic peptide (CNP) and the C-terminus isolated from the dendroapis natriuretic peptide (DNP) of the venom from the green mamba. In early studies, intravenous and subcutaneous infusion of cenderitide was reported to reduce left ventricular (LV) mass and ameliorate cardiac remodelling. In this work, biodegradable polymeric films encapsulating CD-NP were developed and were investigated for their in vitro release and degradation characteristics. Subsequently, the bioactivity of released peptide and its effects on human cardiac fibroblast (HCF) were explored. We achieved sustained release from three films with low, intermediate and high release profiles for 30 days. Moreover, the bioactivity of released peptide was verified from the elevated production of cyclic guanosine monophospate (cGMP). The CD-NP released from films was able to inhibit the proliferation of hypertrophic HCF as well as suppress DNA synthesis in HCF. Furthermore, the sustained delivery from films showed comparable or superior suppressive actions on hypertrophic HCF compared to daily infusion of CD-NP. The results suggest that these films could be used to inhibit fibrosis and reduce cardiac remodelling via local delivery as cardiac patches.

UR - http://www.scopus.com/inward/record.url?scp=84879817280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879817280&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0068346

DO - 10.1371/journal.pone.0068346

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e68346

ER -